Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response. The aim of this study was to determine IL-18 levels in serum of patients with Bronchiectasis and to investigate whether macrolide attenuate its levels.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jin-Fu Xu
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

1. Able to provide written informed consent.

2. Confirmed diagnosis of bronchiectasis by HRCT.

3. Aged 18-85 years.

Exclusion Criteria:

1. Bronchiectasis as a result of CF or active tuberculosis or non-tuberculous mycobacterial (NTM) infection.

2. Allergy to macrolide antibiotics

3. Any history of severe cardiopulmonary dysfunction, eg. left heart failure, Unstable cardiac arrhythmias

4. pregnant or nursing

5. hypogammaglobulinemia or other autoimmune disease 6. diagnosed with ABPA